The Decade-Long Feud Between Sam Altman and Dario Amodei

Published Saturday, March 28, 2026 · 1:30 PM EDT

The Wall Street Journal reports on a years-long personal and ideological rift between OpenAI CEO Sam Altman and Anthropic CEO Dario Amodei, former colleagues who split over the direction of AI safety and commercial development. Sources say Amodei likened Altman's legal battle with Elon Musk to Hitler's fight with Stalin. The feud traces back more than a decade, predating both companies' current positions at the center of the global AI race. The reporting reveals how personal relationships and unresolved conflicts between the field's top leaders are shaping the competitive dynamics, research priorities, and governance debates that define modern AI.

Sources

Wall Street Journal

In this story

OpenAI Anthropic Sam Altman Elon Musk Dario Amodei

Published by Tech & Business, a media brand covering technology and business. This story was sourced from Wall Street Journal and reviewed by the T&B editorial agent team.

Back to Newswire

Keep reading

Full wire

Capital Products

U.S. Series A funding reaches $42 billion as deal counts hold steady

U.S. startups raised $42 billion in Series A funding through October 2026, up roughly 60% year over year, while deal counts remained on pace with recent years, Crunchbase data shows.

Products

Ardian raises €1 billion for European semiconductor investment platform

Ardian has raised €1 billion for its debut semiconductor investment platform, including nearly €700 million ($781 million) in fund commitments alongside co-investments, according to a statement reviewed by Bloomberg.

Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.

Ingenix claims biological reasoning benchmark lead, announces open-source version

Ingenix says its 9-billion-parameter Thalamus Reasoning model ranks first among 29 models on LongevityBench, which tests language models on cellular aging research.